Advancing Innovative Botanical Therapies for Neurological and Inflammatory Diseases
We are advancing a pipeline of innovative, multi-target botanical therapies to address neurodegenerative and inflammatory diseases. Our lead candidate, CNR-401, represents a critical step toward delivering safe, effective treatments for underserved patient populations.
CNR-401: Innovating Neurodegenerative Care
CNR-401 optimizes traditional cannabinoid therapies with cannflavin A and terpenoids to target multiple disease pathways in ALS. ALS is a complex, progressive disease with limited treatment options. CNR-401’s synergistic formulation is designed to reduce neuroinflammation, alleviate symptoms, and offer neuroprotective benefits—offering patients with ALS renewed hope and the potential for an improved quality of life where current treatments fail.
With its pipeline-in-a-product strategy, CNR-401 has the potential to expand into other neurodegenerative diseases like Alzheimer’s and Frontotemporal Dementia (FTD), where similar disease mechanisms are at play.
CBD
Other Minor Cannabinoids
Terpenoids
CFA
CNR-100s: Inflammation
Canurta’s CNR-100 candidates are focused on tackling chronic inflammatory conditions such as rheumatoid arthritis, juvenile arthritis, and respiratory diseases. These therapies inhibit two key inflammatory pathways—mPGES-1 and 5-LO—to provide dual inhibition and block the production of proinflammatory molecules.
CNR-400s: Neurology
Canurta’s CNR-400 candidates target neurodegenerative diseases like ALS, Alzheimer’s, and FTD by inhibiting enzymes (MAGL and FAAH) that contribute to inflammation. By protecting brain cells from inflammatory damage, these therapies hold significant promise for slowing disease progression and improving quality of life.
Canurta's Pipeline